- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update | 80 | PR Newswire | CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company... ► Artikel lesen | |
| CITIUS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 03.04. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.02. | Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update | 208 | PR Newswire | CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company... ► Artikel lesen | |
| 14.02. | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.02. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | CITIUS ONCOLOGY, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 06.01. | Citius Oncology weighs strategic options on road to launching newly-approved lymphoma med | 1 | FiercePharma | ||
| 06.01. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update | 395 | PR Newswire | CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company... ► Artikel lesen | |
| 27.12.24 | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | CITIUS ONCOLOGY, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 11.11.24 | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | 183 | PR Newswire | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| 12.08.24 | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. | 233 | PR Newswire | LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA
Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.
Shares of Citius Oncology, Inc.... ► Artikel lesen | |
| 09.08.24 | TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market Update | 809 | GlobeNewswire (Europe) | New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) ("TenX"), a publicly traded special purpose acquisition company, was notified by... ► Artikel lesen | |
| 05.08.24 | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. | 380 | PR Newswire | Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc.
Citius Pharmaceuticals to retain approximately 90% majority control post transaction... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 32,600 | -0,46 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
| QIAGEN | 40,325 | +1,42 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
| NOVAVAX | 6,280 | +0,30 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| STRYKER | 336,10 | +0,27 % | Former Intuitive, Stryker VP joins Think Surgical as EVP to advance surgical robot tech | ||
| ILLUMINA | 73,09 | +0,27 % | Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? | ||
| CRISPR THERAPEUTICS | 33,600 | +0,60 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| AAP IMPLANTATE | 1,310 | 0,00 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
| OCUGEN | 0,773 | +0,10 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,440 | +1,34 % | Sangamo stock holds $10 target from H.C. Wainwright on trial optimism | ||
| INTELLIA THERAPEUTICS | 6,588 | -1,94 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,612 | +1,38 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| DEFENCE THERAPEUTICS | 0,502 | +1,01 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,796 | +1,41 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| KUROS BIOSCIENCES | 26,180 | -1,73 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen |
CITIUS ONCOLOGY INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,939 Euro und damit +2,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITIUS ONCOLOGY INC finden Sie auf Wallstreet Online.